Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment

OBJECTIVE: Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and c-MET; therefore, it exhibits both antitumor and anti-angiogenetic activities...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Zhao, Yizhuo, Wang, Qiming, Zhang, Li, Shi, Jianhua, Wang, Zhehai, Cheng, Ying, He, Jianxing, Shi, Yuankai, Yu, Hao, Zhao, Yang, Chen, Weiqiang, Luo, Yi, Wang, Xiuwen, Nan, Kejun, Jin, Faguang, Dong, Jian, Li, Baolan, Liu, Zhujun, Han, Baohui, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372914/
https://www.ncbi.nlm.nih.gov/pubmed/30766754
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372914/
https://www.ncbi.nlm.nih.gov/pubmed/30766754
http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0158

Ejemplares similares